{
  "docId": "019de074-48ca-708b-9817-9b094467f30f",
  "docSlug": "b3581031b12373a5077a05b88a8907f5",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 45,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a comparison layout to detail two distinct drug development programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-48ca-708b-9817-9b094467f30f/20",
  "deckHref": "/decks/019de074-48ca-708b-9817-9b094467f30f",
  "deckJsonHref": "/decks/019de074-48ca-708b-9817-9b094467f30f.json",
  "deckAnchorHref": "/decks/019de074-48ca-708b-9817-9b094467f30f#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "NSCLC = non-small cell lung cancer; PD-1 = programmed cell death protein 1; CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; TIGIT = T cell immunoreceptor with Ig and ITIM domains; SoC = standard of care; Fab = fragment. Collaboration partners: Daiichi Sankyo (Dato-DXd).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "509b0b75-546b-41f9-802f-1df9db55e0bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.1,
        "x": 0.03,
        "y": 0.228
      },
      "kind": "image",
      "text": "Molecular structure illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "065459f6-0d69-4f39-9cbb-64b6af3402bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.14,
        "y": 0.228
      },
      "kind": "list",
      "text": "volrustomig PD-1/CTLA-4 bispecific: Accelerated development in CTLA-4 sensitive tumour types; Longer follow-up data for 750mg dose supports transition to late-stage; Five Phase IIIs planned in 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57348d98-ae42-4cfb-978b-b11194b0cdcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.56,
        "y": 0.228
      },
      "kind": "list",
      "text": "rilvegostomig PD-1/TIGIT bispecific: ARTEMIDE-01 Phase II first patient dosed in NSCLC; New Phase III planned to initiate in 2023; Expanded Phase II programme in development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbafc2d0-8eca-47d8-b760-84c38feca9ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Novel bispecific programmes advance with new pivotal trials, including in NSCLC",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d52f296-7cd2-4e4e-8417-4740525c8531",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology: R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da19e4c2-7bf3-40d3-a692-9c10673c9b25",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "18107eda-4090-473e-bbf4-20d9925bf6b3",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck provides detailed information on financial results, oncology performance, and pipeline progress to satisfy the audience's need for information",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "6bc4b448-942a-484e-8a92-bc0a89369cb4",
      "evidence": "The deck presents a logical chain of information to support the company's growth prospects",
      "position": 0,
      "objective": "To demonstrate the company's growth potential",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}